Completed PHASE1 INTERVENTIONAL 2-arm NCT03802786

Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects

An Open-label, Single-dose, Parallel-group Study to Assess the Pharmacokinetics of Imeglimin in Subjects With Moderate Hepatic Impairment Compared to Matched Healthy Control Subjects

Sponsor: Poxel SA

Conditions Hepatic Impairment

Interventions Imeglimin

Updated 5 times since 2019 Last updated: Aug 10, 2020 Started: Nov 6, 2018 Primary completion: Jul 3, 2019 Completion: Jul 8, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Hepatic Impairment, this trial is completed. The trial is conducted by Poxel SA and has accumulated 5 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Sep 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Feb 2019 — Sep 2020 [monthly]

Recruiting PHASE1

First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Poxel SA

Data source: Poxel SA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Munich, Germany